Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Single Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Next Previous
Trial Profile

A Single Center, Single Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TIX 100 (Primary)
  • Indications Diabetes mellitus; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors TIXiMED

Most Recent Events

  • 29 May 2025 According to a TIXiMED media release, the company announced successful completion of the Phase 1 Single Ascending Dose (SAD) study for TIX100. The company is now preparing to initiate a Phase 1 Multiple Ascending Dose (MAD) study.
  • 27 Feb 2025 According to a TIXiMED media release, company look forward to evaluating the findings of the next, higher dose cohorts in the coming months and to a successful completion of the SAD trial later this year.
  • 27 Feb 2025 According to a TIXiMED media release, today announced successful dosing of the first dose cohort in the Phase 1 Single Ascending Dose (SAD) trial of TIX100.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top